Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)- N-(tetrahydro-2 H-pyran-4-yl)piperidin-4 Amine
2. Btrx-335140
3. Cym-53093
1. Btrx-335140
2. 2244614-14-8
3. Cym-53093
4. Xk5ilz28ki
5. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-n-(tetrahydro-2h-pyran-4-yl)piperidin-4 Amine
6. 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-n-(tetrahydro-2h-pyran-4-yl)piperidin-4-amine
7. 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-n-(oxan-4-yl)piperidin-4-amine
8. 4-piperidinamine, 1-(6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-quinolinyl)-n-(tetrahydro-2h-pyran-4-yl)-
9. Unii-xk5ilz28ki
10. Nmra-140
11. Chembl4592045
12. Schembl20670520
13. Gtpl10452
14. Btrx335140
15. Dtxsid401104655
16. Bcp32121
17. Cym53093
18. Ex-a5654
19. Bdbm50531908
20. Compound 58 [pmid: 30707578]
21. Hy-124754
22. Cs-0087593
23. Btrx 335140; Btrx335140; Cym-53093; Cym 53093; Cym53093
| Molecular Weight | 453.6 g/mol |
|---|---|
| Molecular Formula | C25H32FN5O2 |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 453.25400344 g/mol |
| Monoisotopic Mass | 453.25400344 g/mol |
| Topological Polar Surface Area | 76.3 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 630 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for major depressive disorder.
Lead Product(s): Navacaprant,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2025
Lead Product(s) : Navacaprant,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Reports KOASTAL-1 Data for Navacaprant in Major Depression
Details : NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for major depressive disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2025
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for bipolar depression.
Lead Product(s): Navacaprant,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024
Lead Product(s) : Navacaprant,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neumora Announces Initiation of Ph 2 Study of Navacaprant in Bipolar Depression
Details : NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for bipolar depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2024
Details:
NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD.
Lead Product(s): Navacaprant,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: BlackThorn Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2023
Lead Product(s) : Navacaprant,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BlackThorn Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMRA-140 (navacaprant) is a highly selective, novel kappa opioid receptor (KOR) antagonist being developed as a potential monotherapy treatment for MDD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2023
Details:
The funding will support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates including BTRX-335140 (NMRA-140) for neuropsychiatric disorders and neurodegenerative diseases and the development of precision neuroscience platform.
Lead Product(s): Navacaprant,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Abu Dhabi Growth Fund
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 11, 2022
Lead Product(s) : Navacaprant,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Abu Dhabi Growth Fund
Deal Size : $112.0 million
Deal Type : Series B Financing
Neumora Therapeutics Announces $112 Million Series B Financing
Details : The funding will support the advancement of a broad clinical and preclinical pipeline of novel precision medicine candidates including BTRX-335140 (NMRA-140) for neuropsychiatric disorders and neurodegenerative diseases and the development of precision n...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 11, 2022
Details:
BTRX-335140 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Lead Product(s): Navacaprant,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Neumora therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2020
Lead Product(s) : Navacaprant,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Neumora therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
Details : BTRX-335140 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
43
PharmaCompass offers a list of Navacaprant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Navacaprant manufacturer or Navacaprant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Navacaprant manufacturer or Navacaprant supplier.
PharmaCompass also assists you with knowing the Navacaprant API Price utilized in the formulation of products. Navacaprant API Price is not always fixed or binding as the Navacaprant Price is obtained through a variety of data sources. The Navacaprant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Navacaprant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Navacaprant, including repackagers and relabelers. The FDA regulates Navacaprant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Navacaprant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Navacaprant supplier is an individual or a company that provides Navacaprant active pharmaceutical ingredient (API) or Navacaprant finished formulations upon request. The Navacaprant suppliers may include Navacaprant API manufacturers, exporters, distributors and traders.
Navacaprant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Navacaprant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Navacaprant GMP manufacturer or Navacaprant GMP API supplier for your needs.
A Navacaprant CoA (Certificate of Analysis) is a formal document that attests to Navacaprant's compliance with Navacaprant specifications and serves as a tool for batch-level quality control.
Navacaprant CoA mostly includes findings from lab analyses of a specific batch. For each Navacaprant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Navacaprant may be tested according to a variety of international standards, such as European Pharmacopoeia (Navacaprant EP), Navacaprant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Navacaprant USP).
